ProQR Therapeutics Valuation Multiples

ProQR Therapeutics Overview

About ProQR Therapeutics

ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.

Founded

2012

HQ

Employees

166

Website

proqr.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $21M

EBITDA: ($40M)

EV

$119M

Valuation Multiples

Multiples.vc

Start free trial

ProQR Therapeutics Financials

ProQR Therapeutics reported last 12-month revenue of $21M and negative EBITDA of ($40M).

In the same LTM period, ProQR Therapeutics generated $21M in gross profit, ($40M) in EBITDA losses, and had net loss of ($51M).

ProQR Therapeutics P&L

In the most recent fiscal year, ProQR Therapeutics reported revenue of $19M and EBITDA of ($45M).

ProQR Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX

ProQR Therapeutics Stock Performance

ProQR Therapeutics has current market cap of $209M, and enterprise value of $119M.

ProQR Therapeutics' stock price is $1.98.

ProQR Therapeutics Valuation Multiples

ProQR Therapeutics trades at 5.8x EV/Revenue multiple, and (3.0x) EV/EBITDA.

ProQR Therapeutics Financial Valuation Multiples

As of April 11, 2026, ProQR Therapeutics has market cap of $209M and EV of $119M.

Equity research analysts estimate ProQR Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

ProQR Therapeutics has a P/E ratio of (4.1x).

ProQR Therapeutics Margins & Growth Rates

ProQR Therapeutics' revenue in the last 12 month grew by 23%.

ProQR Therapeutics' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.4M for the same period.

ProQR Therapeutics' rule of 40 is 23% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

ProQR Therapeutics' rule of X is 92% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

ProQR Therapeutics Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

ProQR Therapeutics M&A Activity

ProQR Therapeutics acquired XXX companies to date.

Last acquisition by ProQR Therapeutics was on XXXXXXXX, XXXXX. ProQR Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

ProQR Therapeutics Investment Activity

ProQR Therapeutics invested in XXX companies to date.

ProQR Therapeutics made its latest investment on XXXXXXXX, XXXXX. ProQR Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).